Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ36MR)

This product GTTS-WQ36MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF17 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001192.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 608
UniProt ID Q02223
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ36MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11334MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-524
GTTS-WQ4536MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-936558
GTTS-WQ12911MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ8747MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IBI-101
GTTS-WQ5955MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CL-2C
GTTS-WQ7073MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ11764MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MK-1308
GTTS-WQ15904MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA XOMA 052
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW